Introduction
Targeted BCR-ABL inhibition with imatinib has improved outcome for chronic myelogenous leukemia (CML).
attributed solely to mutations in the ABL kinase domain (BCR-ABL MUTANTS ). 4 We previously developed a murine leukemia model of Ph+ ALL, using primary, polyclonal Arf -/-p185 BCR-ABL luciferase-expressing (Luc+) leukemia-initiating pre-B cells (LICs), which captures key genetic features of human Ph+ ALL (i.e., BCR-ABL expression and CDKN2A deletion) and enables in vivo luminescent imaging to monitor response to therapy. 5 Such BCR-ABL WT LICs retain phenotypic and signaling properties essential for suspended leukemic blasts to interact with the surrounding host environment 6 not typically present in established leukemic cell lines and remain responsive to cytokines implicated in murine pre-B-cell development both in vitro and in vivo. 6 These polyclonal BCR-ABL WT LICs can very efficiently initiate leukemias in syngeneic, immune-competent mice. 6 In "recipient" host mice engrafted with these LICs, residual BCR-ABL WT cells 5 evade treatment with BCR-ABL inhibitors, paralleling what is seen in human Ph+ ALL patients. 4 BCR-ABL kinase domain (KD) mutations, including BCR-ABL T315I (resistant to imatinib, dasatinib, and nilotinib), emerge only after long-term exposure to BCR-ABL-KIs. 5, 7 In contrast to the in vivo setting, BCR-ABL WT murine and human cells are quite sensitive to BCR-ABL-KIs in vitro. 8 This disparity between in vitro and in vivo sensitivity implicates the host microenvironment in attenuating the therapeutic response to BCR-ABL kinase inhibition. We previously reported that common γ chain receptor host cytokines modulate primary imatinib resistance, 6 and other host-derived growth factors have been shown to attenuate BCR-ABL kinase inhibition. [9] [10] [11] Currently, no consensus exists on the relative importance of host cytokines or growth factors that attenuate the cellular responses to BCR-ABL-targeted agents.
We used a naive screening approach to identify interleukin (IL)-7 as the most potent among candidate host growth factors in inducing resistance to BCR-ABL-KIs in Ph+ ALL. Following on that study, we used a repurposing screen of existing drugs and clinical candidates to identify drugs that blocked proliferation of BCR-ABL WT LICs cultured with murine IL-7. This study identified both the majority of known antileukemic drugs and a few novel agents that could overcome cytokinedependent cell survival signaling. Testing of combinations of these validated hits with dasatinib revealed that the antimalarial drug dihydroartemisinin (DHA) provides strong synergy with BCR-ABL-KIs against Ph+ ALL cells responding to the tumor microenvironment. When used in vivo, DHA-dasatinib combination therapy eradicates dasatinib-refractory leukemia in vivo, providing near-complete long-term survival.
Materials and Methods

Development of LIC-Based Screening Assay
Before use in any in vitro assay, LICs had to pass the following quality control parameters: test thawing (benchmark: 95% viability at 24 h), PCR genotyping to confirm Arf -/-status, mycoplasma testing (negative by Takara Bio Mycoplasma PCR assay [Clontech, Madison, WI]), sequence verification of the BCR-ABL allele, and in vitro dasatinib potency confirmation.
The maximum DMSO concentration tolerated by LICs in culture was determined to be 0.2% (by volume) and was maintained at ≤0.1% (by volume) in all subsequent work. LICs were plated in 384-well microplates at a cellular density of 5 × 10 4 per milliliter (1250 LICs per well in 25 µL BCM10) and confirmed to give exponential growth during the first 72 h (Suppl. Fig. S1 ). To select assay reagents, three high-throughput screening (HTS) relevant cellular assays were evaluated according to the manufacturer's instructions (see Suppl . Fig. S3 ). The luminescent CTG (CellTiter-Glo; Promega, Madison, WI) assay, which monitors cellular adenosine triphosphate (ATP) content, accurately detected a low number of LICs, producing results comparable to those obtained by flow cytometry, and provided ease of use in HTS (no prolonged incubation step required between reagent addition and assay readout). When carried out after 72 h, the CTG assay had a 10,000-fold dynamic range, had low signal variance (Z′ = 0.9 in semi-automated mode and Z′ = 0.8 in fully automated mode), displayed minimal drift or edge effects, and had robust interplate and interday reproducibility.
Forward Cytokine Phenotypic Screen
Lyophilized murine and human recombinant cytokines (R&D Systems, Minneapolis, MN) were diluted with 1 mg/mL bovine serum albumin (BSA) in sterile phosphate-buffered saline (PBS) to a final concentration of 20 µg/mL and stored at 4 °C. Antileukemia drugs, BCR-ABL-KIs, and non-BCR-ABL-specific KIs (LC labs; Sigma, St. Louis, MO) were solubilized in DMSO to obtain 10-mM stock concentrations. Subsequent serial titrations were prepared using DMSO in 0.5-mL vials or 384-well drug master plates and stored at -20 °C.
To study the impact of murine cytokines on dasatinib action, LIC stocks containing different concentrations of candidate cytokines were prepared in multichannel sterile reservoirs and plated into 384-well plates. Drug delivery to cell suspensions was accomplished with a V & P Scientific (San Diego, CA) pin tool (Suppl . Table S1 ). For murinehuman comparisons, human SUP-B15 Ph+ ALL cells (DSMZ cell culture collection, Liebniz, Germany) in McCoy's media containing 20% fetal calf serum and penicillin/streptomycin (Invitrogen, Carlsbad, CA) were plated at 12,500 cells in 25 µL/well in black clear-bottom 384-well microplates. Drugs were transferred by pin transfer. After a 72-h incubation at 37 °C, 20% (by volume) MTS assay reagent (CellTiter 96 Aqueous One Solution; Promega) was added, and microplates were incubated for 75 min at 37 °C and read colorimetrically at 490 nm.
High-Throughput Phenotypic Drug Screening
The IL-7 concentration of 0.85 ng/mL was confirmed (cytokine titration assays similar to Fig. 1a for dasatinib) to confer near-maximal and reproducible resistance against nilotinib and imatinib in BCR-ABL WT LICs (Fig. 1b and Suppl. Table S1 ). Primary screening of a collection of 5600 compounds (see supplementary information for details) highly enriched for approved drugs, development candidates, and compounds of known cellular activity from a variety of signaling mechanisms was carried out at a fixed dose (10 µM). Active compounds were retested to establish potency using a 10-step, 2-fold dilution scheme (see main text and Suppl. Table S1 ). In addition to BCR-ABL WT and BCR-ABL T315I LICs, secondary drug screens were also performed against BCR-ABL F317L LICs, another clinically known dasatinib-resistant ABL KD mutation, which gave identical results to that for BCR-ABL T315I (not shown). Multiple control assay plates were set up during all screening runs to allow for interplate and interday comparisons at 0, 24, 48, and 72 h. 
Supplementary Data
Supplementary data include (1) supplemental information (PDF), which contains materials and methods for generation of LICs, cytokine screening, fluorescence-activated cell sorting (FACS) assessment of viability and cell cycle percentages, detailed description of chemical library screened, data processing, quality control and hit scoring criteria for high-throughput (HT) drug screens, cluster analysis using therapeutic drug classes, Supplemental Figures S1 to S11, Supplemental Table S1 , and references, and (2) an Excel supplement containing complete data sets for cytokine and HT drug screens.
Results
Determining Which Leukemia Microenvironment Cytokines Induce Drug-Resistance against BCR-ABL-KIs
In the absence of drug treatment, both Fig. S1 ) and demonstrate similar, potent leukemia initiation capacity and aggressive progression in vivo (Suppl. Fig. S2 ). They retain both phenotypic and signaling characteristics of leukemic blasts, suggesting that they are a ready model for the effects of cytokines upon blasts. Fifteen leukemia microenvironment cytokines were evaluated for their ability to protect murine BCR-ABL WT LICs from dasatinib in vitro.
IL-7 provided the strongest protection against dasatinib (Fig. 1a) . In addition, IL-3, thymic stromal lymphopoietin (TSLP, IL-7-like cytokine), and IL-4 conferred some resistance but with greatly reduced potency. In contrast, transforming growth factor-β (TGF-β) enhanced dasatinib activity. In addition, IL-7 significantly attenuated the potency of all Food and Drug Administration (FDA)-approved BCR-ABL-KIs against murine BCR-ABL WT LICs (Fig. 1b) and the human Ph+ ALL cell line SUP-B15 (Fig. 1c) . However, IL-7 did not affect the potency of tested non-BCR-ABL-targeted drugs (Suppl. Fig. S4 ). Thus, IL-7 drives a specific cellular response that provides resistance to all clinically available BCR-ABL-KIs. The specificity was further confirmed by three in vitro findings: (1) the presence of IL-7 during prolonged dasatinib treatment significantly increased viability of Arf -/-BCR-ABL WT LICs (Suppl. Fig. S5 ), (2) transient BCR-ABL inhibition dramatically increased LIC responsiveness to IL-7 (Suppl. Fig. S6c,d ), 13 and (3) removing IL-7 completely reversed the protection effect and restored dasatinib's potency (data not shown).
Physiological Levels of IL-7 Confer an Aggressive, Dasatinib-Resistant Phenotype to Ph+ ALL In Vivo
To confirm the physiological relevance of this finding, we studied the effect of IL-7 on leukemia progression and dasatinib responsiveness in vivo. Implantation of IL-7 +/+ , but not IL-7 -/-, host mice with relatively small numbers of BCR-ABL WT LICs (200, low-burden model) led to decreased survival (Fig. 1d) , suggesting that murine Ph+ ALL progression accelerates in response to IL-7. Injecting higher numbers of LICs (200,000) overcame this trend (200,000, high-burden model; Fig. 1e) , suggesting the phenomenon is most important during expansion of the initial seeding leukemia cell population. Treatment of animals in the high-burden model revealed a significantly shortened survival benefit from dasatinib monotherapy of BCR-ABL WT -driven leukemias in IL-7-deficient hosts (Fig. 1e) . From a therapeutic perspective, these findings show that in vivo responses to dasatinib therapy in Ph+ ALL are modulated by IL-7, independent of BCR-ABL KD mutations. These studies also suggest that using the BCR-ABL WT LICs in the presence of IL-7 as a screening system could identify physiologically relevant pharmacological approaches to reversing this cytokine-dependent drug resistance.
High-Throughput Screens against Primary (IL-7-Induced) and Acquired (BCR-ABL Mutation) BCR-ABL-KI Drug-Resistant Phenotypes
We hypothesized that pharmacologic agents could be identified that would overcome IL-7-induced BCR-ABL-KI resistance. A collection of 5600 compounds highly enriched for approved drugs, development candidates, and compounds of known cellular activity from a variety of signaling mechanisms, including all active ingredients from approved oncology and anti-infective drugs, was screened against BCR-ABL WT and BCR-ABL T315I LICs in the presence of IL-7 (0.85 ng/mL) at a fixed drug concentration (10 µM). The quality of the screen and minimum significant activity (>10% growth inhibition) were confirmed by receiver operating characteristic analysis and other statistical metrics (Suppl. Fig. S7-S10 ). In total, 627 compounds showed statistically significant activity (≥10% growth inhibition). These hits were augmented with available structural analogues and drugs of the same pharmacologic classes to yield 706 active compounds. Concentration-response relationships were established for these compounds against BCR-ABL WT and drug-resistant BCR-ABL T315I LICs in the presence of IL-7, giving 229 validated hits with reasonable potency, representing a final hit rate of 4%. While a high hit rate, this is congruent with our historical experience screening this collection in growth inhibitory assays against cancer cell lines and primary cultures. All validated hits were equipotent in inhibiting the growth of BCR-ABL WT and BCR-ABL T315I LICs, suggesting they are not acting through BCR-ABL. This set included 15 conventional antileukemic drugs (see Excel supplement), some of which enhance BCR-ABL-KI therapy in vivo, 3, 5 thus validating the detection of appropriate phenotypic responses. Furthermore, cluster analysis indicated that this set effectively sampled the space of all existing therapeutic classes (Fig. 2) . See Excel supplement for a detailed annotation of validated hits.
In Vitro and In Vivo Anti-Ph+ ALL Activity of DHA
Although our validated hits included compounds with varying mechanisms of action and compounds in varying stages of development, we focused on approved drugs with favorable human pharmacokinetic and toxicity profiles that have previously been used with pediatric populations but not for leukemia, which quickly narrowed focus to the artemisinin class of antimalarials (ARTs), which includes artemisinin, artesunate, and DHA.
14 As a class, the ARTs were equipotent against BCR-ABL WT and BCR-ABL T315I LICs (Fig. 3a) , but the anti-LIC potency of artemisinin (ca. 1 µM EC 50 ) was weaker than that of artesunate or DHA (ca. 200 nM EC 50 ). DHA and artesunate also killed the human Ph+ ALL cell line SUP-B15 with similar potency in the presence of IL-7 (Fig.  3a,b) . Studies have shown that DHA kills other genotypes of leukemic cells while selectively sparing normal human lymphocytes. 15, 16 Therefore, DHA was chosen for further analysis because of its potency, cellular selectivity, oral formulation, favorable pharmacokinetics, known bioavailability in the hematopoietic system, and tolerability in all human age groups.
Due to our interest in modeling the approved drug DHA, which is given orally for malaria, follow-up studies in vivo used the oral route rather than the parenteral route more commonly used in oncology studies. DHA monotherapy conferred a significant dose-dependent survival benefit to IL-7 +/+ host mice bearing low-burden BCR-ABL WT leukemia (Fig. 3c) , although this required escalation to high doses (300 mg/kg) for maximal effect. During these studies, no significant changes in body weight were observed. This dose falls within the tolerated and bioavailable doses used in prior animal modeling for malaria. 17 By conventional allometry, this dose corresponds to roughly 45 mg/kg in a human, which is 4-fold higher than the highest dose used for malaria treatment in humans (up to 12 mg/kg). The limited murine pharmacokinetic data for DHA 18 indicates that it is more rapidly cleared in mice and has lower bioavailability than in humans, suggesting that lower relative doses would be efficacious in humans. In addition, existing human and murine pharmacokinetic data indicate that plasma concentrations that should be achieved in this model would be well above concentrations efficacious in vitro against LICs, even at doses more closely aligned with those used for malaria. 19 BCR-ABL mutations, which are often selected with dasatinib treatment in this model, 5, 7 were absent in leukemic samples collected from terminally moribund DHA-treated mice. DHA monotherapy also gave a similar response in mice with low-burden BCR-ABL T315I leukemia, which is completely refractory to dasatinib (Fig. 3d) . Thus, unlike BCR-ABL-KIs, DHA acts against Ph+ ALL via a BCR-ABL kinase-independent mechanism.
DHA Synergistically Enhances Response to Dasatinib
Because BCR-ABL WT leukemias in IL-7-deficient mice were more sensitive to dasatinib (Fig. 1e) , and DHA displayed anti-Ph+ ALL activity in IL-7 +/+ host mice (Fig. 3c,d) , the potential for synergy between the two drugs was evaluated. Cohorts of IL-7 +/+ immune-competent mice bearing high burdens of Arf -/-BCR-ABL WT -driven leukemia were treated with dasatinib alone (10 mg/kg), DHA alone (200 or 300 mg/kg), or binary combinations (Fig. 4a) . Despite continuous monotherapy, dasatinib induced only weak initial responses, and all animals later relapsed ( Fig. 4b) with complete mortality within 6 weeks of initiating therapy (Fig. 4a) . DHA alone was completely ineffective (200 mg/kg) or poorly effective (300 mg/kg) in the high-burden leukemia model (Fig. 4a) . However, the combination of DHA and dasatinib provided a strong and rapid initial response and led to significantly increased overall survival (Fig. 4a,b) in comparison to the treatment with either of the two drugs alone. Of the 12 mice given 200 mg/kg DHA and 10 mg/kg dasatinib, 3 survived long term. All mice given 300 mg/kg DHA and 10 mg/ kg dasatinib (n = 12) survived the treatment period. As discussed above, the plasma concentrations expected to be reached with such doses are likely providing exposure well above that efficacious against LICs and within those that could be reached in humans with good tolerability. 17, 19 Four weeks after completion of combination therapy, one mouse succumbed to an isolated CNS relapse, which may be related to the poor CNS availability of dasatinib. 20 Remarkably, the 14 surviving mice taken off dasatinibcombined therapy (3/12 at 200 mg/kg and 11/12 at 300 mg/ kg DHA) showed no leukemia for 1 year, the longest period monitored. In this leukemia model, all animals left untreated succumbed to full-blown leukemia within 4 weeks of injecting very low numbers of LICs (Suppl. Fig. S2 ), strongly suggesting that the drug combination cured the disease. All dasatinib-DHA regimens were well tolerated in leukemic and nonleukemic mice, with no noticeable changes in weight gain or clinical signs, in congruence with prior rodent work using similar dosages of DHA.
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Discussion
We identified IL-7 as the dominant (most potent) cytokine that confers resistance to all FDA-approved BCR-ABL inhibitors. IL-7 is essential for murine T-cell and B-cell development, 21 has recently been implicated in human postfetal B-cell development, 21, 22 and is a major contributor to the regulation and maintenance of mature T-lymphoid cells.
23 IL-7-rich niches such as bone marrow harbor early persistent drug-refractory leukemias in dasatinib-treated mice, at which point the vast majority of leukemic cells do not harbor BCR-ABL KD mutations. 5 Ultimately, BCR-ABL mutations emerge under continuous drug exposures, 5, 24 causing secondary drug resistance. Our findings suggest that IL-7 maintains leukemic cell viability, probably through induction of phosphorylation of STAT5, despite continuous BCR-ABL inhibition in vivo, thereby facilitating the subsequent acquisition of drug resistance-conferring kinase domain mutations. There is a well-appreciated relationship between phosphorylation of STAT5 and resistance to imatinib in cells. [25] [26] [27] In addition, human Ph+ ALL patients with increased levels of pSTAT5, whose phosphorylation is triggered by IL-7, respond poorly to imatinib therapy. 27 The demonstration of IL-7-induced drug resistance provided a rationale for "complementing" pharmacological BCR-ABL inhibition with a second drug that induces IL-7-independent leukemic cell death. We assayed 5600 compounds enriched with approved drugs to identify such agents. Our studies confirmed the activities of the majority -driven leukemia were started on daily treatment for 5 days of each week, using two-dose regimens-two vehicles or one vehicle and one agent or two agents (see label), with two doses of each regimen given separately, 8 h apart, by oral gavage. On day 52, all therapy was terminated. (b) For 6 mouse groups in a, separate graphs represent quantitative assessment of serial whole-animal luminescent signals (p/s/cm 2 /sr) acquired weekly. Solid lines represent imaging intensity of signal (y-axis) as a measure of leukemia burden from individual mice in the group, which is traced in real time on the x-axis. On day 7, before initiating therapy, all six groups had comparable and high burden of leukemia. The horizontal dotted line represents the empirically determined lower limit of sensitivity for luminescent signal as an experimental cutoff for detectable levels of persistent leukemia. Rectangular gray box quantifies experimental primary therapeutic response to indicated regimens; box width depicts approximate time (days) to induce maximal initial response, and box depth represents maximal decrease achieved in leukemia burden signal. Increasing depth and decreasing width indicate stronger and quicker primary responses, respectively. of known antileukemia drugs and also identified several new classes of the compounds with activity against both IL-7-cultured wild-type and BCR-ABL mutant LICs. We characterized the antileukemia activity of one such drug: the orally bioavailable, well-tolerated, antimalarial agent DHA, which selectively kills leukemic cells while sparing normal lymphocytes. 15, 16 Mechanistically, DHA acts independently of BCR-ABL-KIs (Fig. 3) . In combination with dasatinib, DHA enhanced the depth of remission induction (Fig. 4b) and achieved near-complete long-term survival in a robust murine model of human Ph+ ALL. It is noteworthy that the combination of DHA and dasatinib therapy is significantly more efficacious than the clinically used triple combination of dasatinib, dexamethasone, and asparaginase when assessed in the same model. 5 Distinct from its antimalarial mechanism of action, induction of cell death by ARTs in transformed cells is associated with accelerating the degradation of c-MYC. 28 c-MYC expression is downstream of activated STAT5, 29 which is maintained by IL-7 signaling, and STAT5 activation 30 and c-MYC expression 31, 32 are necessary to sustain BCR-ABL-transformed cells. This phenomenon has recently been implicated in other stroma-induced drug resistance 10 as well as used as an explanation for resistance to imatinib.
10,33 However, we do not see changes in pSTAT5 levels in response to treatment with artemisinins (data not shown). Thus, DHA may synergize with BCR-ABL-KI therapy by accelerating the degradation of c-MYC, thereby countering the protective effects of IL-7, as has been reported by others. Alternatively, as has also been reported, DHA may affect BCR-ABL levels directly. 34, 35 We have shown that phenotypic screening using primary leukemia cells selected to maintain responsiveness to host cytokines allows identification of therapeutic agents or developmental compounds that hold promise for the treatment of Ph+ leukemias. This system provides an unbiased platform for the discovery of such new therapies and to evaluate the potential utility of such agents by demonstrating proof of concept in vivo using a murine model that closely recapitulates human disease. Finally, our results strongly support further study of BCR-ABL-KI/DHA combination therapy for the treatment of patients with high-risk Ph+ ALL.
